DIAGNOS Announces Grant of Stock Options
October 03 2024 - 2:30PM
Diagnos Inc. ("DIAGNOS" or the "Corporation") (TSX Venture: ADK)
(OTCQB: DGNOF), a pioneer in early detection of critical health
issues through the use of Artificial Intelligence (AI)
technologies, announces a grant of an aggregate number of 1,550,000
stock options to its directors and officers.
Stock options vest at 50% per year, commencing
with the first anniversary of the grant. The date of the grant is
October 3, 2024. The exercise price of the stock options granted
has been established at $0.37 per common share. The expiry date to
which the stock options can be exercised is October 3, 2029.
The grant remains subject to regulatory
compliance including TSX Venture exchange acceptance. All monies
quoted in this press release shall be stated and paid in lawful
money of Canada.
About DIAGNOSDIAGNOS is a publicly traded
Canadian corporation dedicated to early detection of critical
health problems based on its FLAIRE Artificial Intelligence (AI)
platform. FLAIRE allows for quick modifying and developing of
applications such as CARA (Computer Assisted Retina Analysis).
CARA’s image enhancement algorithms provide sharper, clearer
retinal images. CARA is a cost-effective tool for real-time
screening of large volumes of patients.
Additional information is available at
www.diagnos.com and www.sedar.com
This news release contains forward-looking
information. There can be no assurance that forward-looking
information will prove to be accurate, as actual results and future
events could differ materially from those anticipated in these
statements. DIAGNOS disclaims any intention or obligation to
publicly update or revise any forward-looking information, whether
as a result of new information, future events or otherwise. The
forward-looking information contained in this news release is
expressly qualified by this cautionary statement.
Neither the TSX Venture Exchange nor its
Regulation Services Provider (as that term is defined in the
policies of the TSX Venture Exchange) accepts responsibility for
the adequacy or accuracy of this release.
For further information, please contact:
Mr. André Larente, President
DIAGNOS Inc.
Tel: 450-678-8882 ext. 224
alarente@diagnos.ca
Diagnos (TSXV:ADK)
Historical Stock Chart
From Oct 2024 to Nov 2024
Diagnos (TSXV:ADK)
Historical Stock Chart
From Nov 2023 to Nov 2024